Spatiotemporal release of growth factors from a delivery device can profoundly affect the efficacy of bone growth induction. Here, we report on a delivery platform based on the encapsulation of insulin-like growth factor I (IGF-I) in different poly(D,L-lactide) (PLA) and poly(D,L-lactide-co-glycolide) (PLGA) microsphere (MS) formulations to control IGF-I release kinetics. In vitro IGF-I release profiles generally exhibited an initial burst (14-36% of total IGF-I content), which was followed by a more or less pronounced dormant phase with little release (2 to 34 days), and finally, a third phase of re-increased IGF-I release. The osteoinductive potential of these different IGF-I PL(G)A MS formulations was tested in studies using 8-mm metaphyseal drill hole bone defects in sheep. Histomorphometric analysis at 3 and 6 weeks after surgery showed that new bone formation was improved in the defects locally treated with IGF-I PL(G)A MS (n=5) as compared to defects filled with IGF-I-free PL(G)A MS (n=4). The extent of new bone formation was affected by the particular release kinetics, although a definitive relationship was not evident. Local administration of IGF-I resulted in down-regulation of inflammatory marker genes in all IGF-I treated defects. The over-expression of growth factor genes in response to IGF-I delivery was restricted to formulations that produced osteogenic responses. These experiments demonstrate the osteoinductive potential of sustained IGF-I delivery and show the importance of delivery kinetics for successful IGF-I-based therapies.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ejpb.2013.03.004 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Hormonal symphony: The dynamic duo of IGF and EGF in gonadotropin-induced fish ovarian development and egg maturation.
Anim Reprod Sci
February 2025
ICAR-Central Inland Fisheries Research Institute, Barrackpore, Kolkata, West Bengal 700 120, India.
Fish oocyte maturation (FOM) is a critical biological process that occurs before ovulation and is influenced by gonadotropins, particularly luteinizing hormone (LH). The release of LH stimulates the ovarian follicle to produce a maturation-inducing hormone (MIH), specifically 17α, 20β-dihydroxy-4-pregnen-3-one (17α, 20β-DP), which initiates the formation of maturation-promoting factor (MPF) through the activation of cyclin B and cdc2 kinase. Insulin-like growth factor I (IGF-I) significantly regulates ovarian functions, including steroidogenesis, by activating its membrane receptors and the tyrosine kinase pathway.
View Article and Find Full Text PDFGHRH and reproductive systems: Mechanisms, functions, and clinical implications.
Rev Endocr Metab Disord
November 2024
Maimonides Institute for Biomedical Research of Córdoba (IMIBIC), IMIBIC Building. Av. Menéndez Pidal S/N. 14004, Cordoba, Spain.
Article Synopsis
- Growth hormone-releasing hormone (GHRH) is traditionally viewed as a key hormone regulating growth and metabolism through the hypothalamic-pituitary axis, but it's also produced in various peripheral tissues, impacting multiple bodily functions.
- The presence of GHRH and its receptor (GHRH-R) in the reproductive systems of both males and females suggests important roles in gonadal function and reproductive health.
- This review will examine the GHRH/GHRH-R axis's significance in reproductive physiology and discuss how understanding this axis could lead to new treatments for reproductive disorders like infertility, endometriosis, and cancers linked to the reproductive system.
Background: Pituitary lesions after traumatic brain injury (TBI) are frequent in children and adolescents, but the rate of post-TBI central hypothyroidism remains uncertain.
Objective: To identify the long-term incidence of post-TBI CH and the clinical and laboratory characteristics of this complication in children and adolescents.
Methods: The analysis included 31 patients with a history of TBI with at least 1 year of follow-up.
Medical Treatment of Acromegaly: What's New?
Front Horm Res
November 2024
Department of Medicine (DIMED), Clinica Medica 3, Padua University, Padua, Italy.
Acromegaly is a chronic and progressive disorder caused by growth hormone (GH) and insulin-like growth factor 1 (IGF-1) excess, responsible for the onset of multiple systemic complications. Targets of acromegaly treatment are the normalization of hormonal (GH/IGF-1) parameters, the removal/reduction/stabilization of the pituitary mass, the control of existing conditions, and the prevention of new ones, so to improve quality of life and normalize life expectancy. Patients often require a multimodal therapeutic approach, including surgery, medical therapy, and radiotherapy, that allows disease cure/control in the majority of the cases.
View Article and Find Full Text PDFExploitation of the fibrinolytic system by B-cell acute lymphoblastic leukemia and its therapeutic targeting.
Nat Commun
November 2024
Institute of Transfusion Medicine - Transfusion Center, Johannes Gutenberg University Medical Center, 55131, Mainz, Germany.
Article Synopsis
- Fibrinolysis plays a crucial role in the release of hematopoietic stem cells from bone marrow, affecting the development of B-cell acute lymphoblastic leukemia (B-ALL).
- Activation of plasmin, driven by annexin A2, alters the extracellular matrix (ECM), which impacts cancer cell growth by trapping the growth factor IGF1 and hindering signaling pathways.
- Inhibiting plasmin activation with ε-aminocaproic acid (EACA) shows promise in reducing tumor size and extending survival in B-ALL models, suggesting that targeting fibrinolysis could be a helpful addition to cancer treatment.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!